As with most surgeries, venous thromboembolism is always a potential risk and transgender surgical procedures are no different. A new study published in The Journal of Clinical Endocrinology & Metabolism shows no increased clot risk while maintaining hormone therapy during gender affirming surgery. Transgender medicine continues to grow and evolve – more and more people...
Author: Derek Bagley
Phase 3 Trial Results Show Promise for Drug to Treat Severe Hypoglycemia
Earlier this week Diabetes Care published results from a Phase 3 trial evaluating dasiglucagon for the treatment of severe hypoglycemia in adults with diabetes. Zealand Pharma is marketing the drug as Zegalogue. The study found that dasiglucagon administration resulted in a reversal of hypoglycemia (with a median recovery time of 10 minutes) with 99% of...
Robert J. Lefkowitz, MD, first got into research because of the Vietnam War. As described in his new book A Funny Thing Happened on the Way to Stockholm: The Adrenaline-Fueled Adventures of an Accidental Scientist, he joined the United States Public Health Service (USPHS) to avoid being sent to Vietnam as a military doctor in...
Moving is always stressful. Just imagine factoring in social distancing protocols, adhering to California’s earthquake safety standards, and pausing your research to get it done. Joy Y. Wu, MD, PhD, talks to Endocrine News about moving her research lab at Stanford University under less-than-ideal circumstances but she and her team got it done with a...Progression of Acromegalic Arthropathy Observed in Long-Term Study
Radiographic arthropathy progresses significantly in patients with long-term, well-controlled acromegaly, according to a study recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Iris C. M. Pelsma, MD, MSc, of Leiden University Medical Center in The Netherlands, point out that one of the long-term complications of acromegaly is acromegalic arthropathy, which...
Phase 3 Trial Data Shows Positive Results for Oral Treatment of Acromegaly
Data presented last month at ENDO 2021 from Phase 3 of the MPOWERED study showed that oral octreotide capsules improved clinical symptoms and other patient-reported outcomes compared to long-acting injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly. In addition, oral octreotide capsules met the pre-specified non-inferiority margin compared to long-acting iSRLs in maintenance of...
Researchers Determine Best Predictors of Acromegaly Remission Following Transsphenoidal Surgery
Tumor size and random growth hormone concentration at diagnosis are the best predictors for remission of acromegaly after transsphenoidal surgery (TSS), according to a study recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Eva C. Coopmans, MD, of Erasmus University Medical Center in Rotterdam, The Netherlands, point out that TSS...
New Integrated Data Show Promise for Novel Thyroid Eye Disease Drug
New pooled data from Phase 2 and Phase 3 clinical trials further reinforce that teprotumumab-trbw significantly improves proptosis (eye bulging) and diplopia (double vision) for thyroid eye disease (TED) in patients in different subgroups, with most maintaining a long-term response. The results were published recently in The Lancet Diabetes & Endocrinology. Teprotumumab-trbw is a fully human...
